Immunome, Inc. (IMNM)
$ 16.72
-1.12 (-6.28%)
-
| Symbol | IMNM |
|---|---|
| Price | $ 16.72 |
| Beta | 0.000 |
| Volume Avg. | 0.17M |
| Market Cap | 0.202B |
| Shares () | - |
| 52 Week Range | 9.275-63.78 |
| 1y Target Est | - |
| DCF Unlevered | IMNM DCF -> | |
|---|---|---|
| DCF Levered | IMNM LDCF -> | |
| ROE | -43.02% | Strong Sell |
| ROA | -33.46% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 14.17% | Neutral |
| P/E | - | |
| P/B | 3.64 | Strong Buy |
Latest IMNM news
About
Download (Excel)Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.